期刊
CURRENT OPINION IN VIROLOGY
卷 1, 期 6, 页码 548-554出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2011.10.015
关键词
-
类别
资金
- National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN2722011000010C]
- Dixon Foundation
Resurgent interest in antiviral drugs for the treatment of herpesvirus has led to the development of new compounds that are progressing through clinical trials. This is important because there are few therapeutic options for resistant infections and some viruses such as human cytomegalovirus remain underserved. New compounds include conventional DNA polymerase inhibitors such as valomaciclovir and cyclopropavir, as well as CMX001 that has a broad spectrum of antiviral activity that includes all the herpesviruses. It also includes compounds with new molecular targets such as maribavir (MBV), FV-100, AIC361, and AIC246. Recent advances with each of these compounds will be reviewed including their virus specificity, mechanism of action, and stage of development. The potential of these new compounds to improve clinical outcome will also be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据